A Case Study of Inositol and Soluble Fiber Supplementation on Glycemic Control in an Overweight Subject

Authors

  • Haley Serra RDN;Yi Li, PhD Department of Nutrition and Dietetics, Saint Louis University, MO 63103, USA

DOI:

https://doi.org/10.17140/OROJ-8-148

Keywords:

Dietary supplementation; Overweight; Glycemic control; Inositol; Soluble fiber; Type 2 diabetes (T2D); COVID-19

Abstract

Background
Soluble fiber has been shown to improve glycemic control by slowing the absorptions of glucose. And inositol has been shown
to improve glycemic control in type 2 diabetes (T2D) and gestational diabetes via recruiting glucose transporter type 4 (GLUT4)
to cell surface. However, neither inositol supplementation nor combination of inositol and soluble fiber supplementation has
been studied in overweight.
Objective
To investigate if supplementation of inositol improves biological markers of glycemic control overweight and obesity, and that
supplementation of inositol in combination with soluble fiber have synergistic effects to further improve these markers.
Design
A single cohort, uncontrolled, test-retest design was planned to be implemented over 5-weeks in which the participants supplemented 2 grams of myo-inositol twice daily for 4-weeks and then 2 grams of myo-inositol plus 2 grams of soluble fiber each
twice daily for 1-week in overweight and obese subjects. Only one overweight subject was able to complete both phases of
supplementation due to coronavirus disease-2019 (COVID-19), therefore the study is reported as a case study.
Results
Supplementation of 4 grams of myo-inositol daily for 4-weeks resulted in improved glucose parameters and lipid parameters
including fasting blood glucose, post-prandial blood glucose, total blood cholesterol level, blood high-density lipoprotein (HDL)
cholesterol level, and blood triglyceride level. The combination of inositol and soluble fiber supplementation further improved
the total blood cholesterol level.
Conclusion
These results indicate there is potential benefit of inositol supplementation for sub-clinical hyperglycemic, overweight subjects
on glycemic control.

References

Chen DL, Liess C, Poljak A, et al. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. J Clin Endocrinol Metab. 2015; 100(11): 4082-4091. doi: 10.1210/jc.2015-2712

Cignarelli A, Genchi VA, Perrini S, Natalicchio A, Laviola L, Giorgino F. Insulin and insulin receptors in adipose tissue develop-ment. Int J Mol Sci. 2019; 20(3): 759. doi: 10.3390/ijms20030759

Vargas E, Podder V, Sepulveda MAC. Physiology, Glucose Trans-porter Type 4. In: StatPearls. FL, USA: Treasure Island; 2020.

Kawamura T, Takamura C, Hirose M, et al. The factors affect-ing on estimation of carbohydrate content of meals in carbohy-drate counting. Clin Pediatr Endocrinol. 2015; 24(4): 153-165. doi: 10.1297/cpe.24.153

Raymond JL, Morrow K. Raymond, Krause’s Food & the Nutrition Care Process. 14th ed. Amsterdam, Netherlands: Elsevier; 2017: 1152.

Roder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glu-cose homeostasis. Exp Mol Med. 2016; 48: 219. doi: 10.1038/ emm.2016.6

Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol. 2018; 19(1): 31-44. doi: 10.1038/nrm.2017.89

Ahren B. Glucagon--early breakthroughs and recent discoveries. Peptides. 2015; 67: 74-81. doi: 10.1016/j.peptides.2015.03.011

Inoue H. Central insulin-mediated regulation of hepatic glucose production. Endocr J. 2016; 63: 1-7. doi: 10.1507/endocrj.EJ15-

Bachar E, Ariav Y, Ketzinel-Gilad M, Cerasi E, Kaiser N, Lei-bowitz G. Glucose amplifies fatty acid-induced endoplasmic re-ticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS One. 2009; 4(3): e4954. doi: 10.1371/journal.pone.0004954

da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol. 2020; 36(5): 671-682. doi: 10.1016/j.cjca.2020.02.066

Athyros VG, Doumas M, Imprialos KP, et al. Diabetes and lipid metabolism. Hormones (Athens). 2018; 17(360): 61-67. doi: 10.1007/s42000-018-0014-8

Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: A systematic review with meta-analysis of randomized controlled trials. Nutr Rev. 2013; 71(12): 790-801. doi: 10.1111/nure.12076

Abutair AS, Naser IA, Hamed AT. Soluble fibers from psyl-lium improve glycemic response and body weight among diabetes type 2 patients (randomized control trial). Nutr J. 2016; 15: 86. doi: 10.1186/s12937-016-0207-4

Gibb RD, McRorie JW, Russell DA, Hasselblad V, D’Alessio DA. Psyllium fiber improves glycemic control proportional to loss of glycemic control: A meta-analysis of data in euglycemic sub-jects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr. 2015; 6: 1604- 1614. doi: 10.3945/ajcn.115.106989

Ziai SA, Larijani B, Akhoondzadeh S, et al. Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabet-ic outpatients. J Ethnopharmacol. 2005; 102: 202-207. doi: 10.1016/j. jep.2005.06.042

Regidor PA, Schindler AE. Myoinositol as a safe and alter-native approach in the treatment of infertile PCOS women: A german observational study. Int J Endocrinol. 2016; 9537632. doi: 10.1155/2016/9537632 Submit your article to this journal | https://openventio.org/submit-manuscript/

Facchinetti F, Carlomagno G, Gerli S, et al. Results from the international consensus conference on myo-inositol and d-chiro-inositol in obstetrics and gynecology: The link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015; 195: 72-76. doi: 10.1016/j.ejogrb.2015.09.024

Pintaudi B, Di vieste G, Bonomo M. The effectiveness of myo-inositol and d-chiro inositol treatment in type 2 diabetes. Int J En-docrinol. 2016; 2016: 9132052. doi: 10.1155/2016/9132052

Santamaria A, Alibrandi A, Di-Benedetto A, et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: A secondary analysis from 3 RCTs. Am J Obstet Gynecol. 2018; 219: e1-e6. doi: 10.1016/j.ajog.2018.05.018

Rinchai D, Anguiano E, Nguyen P, Chaussabel D. Finger stick blood collection for gene expression profiling and storage of tem-pus blood RNA tubes. F1000Res. 2016; 5: 1385. doi: 10.12688/ f1000research.8841.2

Phillips PJ. Oral glucose tolerance testing. Aust Fam Physician. 2012; 41(6): 391-393.

McRorie JW, McKeown NM. Understanding the physics of functional fibers in the gastrointestinal tract: An evidence-based approach to resolving enduring misconceptions about insoluble and soluble fiber. J Acad Nutr Diet. 2017; 117(2): 251-264. doi: 10.1016/j.jand.2016.09.021

Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009; 40341: 1149-1160. doi: 10.3758/ BRM.41.4.1149

Downloads

Published

2021-12-06

How to Cite

Haley Serra. (2021). A Case Study of Inositol and Soluble Fiber Supplementation on Glycemic Control in an Overweight Subject. Obesity Research, 26–31. https://doi.org/10.17140/OROJ-8-148

Issue

Volume 8 Issue 1 2021

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Obesity Research (OR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.